Last reviewed · How we verify

mAbxience Research S.L. — Portfolio Competitive Intelligence Brief

mAbxience Research S.L. pipeline: 0 marketed, 0 filed, 5 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 5 Phase 3 0 Phase 2 12 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
EU-approved Avastin® EU-approved Avastin® phase 3 VEGF inhibitor (monoclonal antibody) VEGF (Vascular Endothelial Growth Factor) Oncology
EU-Opdivo® EU-Opdivo® phase 3 PD-1 inhibitor PD-1 Oncology
RTXM83 RTXM83 phase 3 PD-1/PD-L1 inhibitor PD-L1 Oncology
US- sourced Opdivo® US- sourced Opdivo® phase 3
MB09 (denosumab biosimilar) MB09 (denosumab biosimilar) phase 3 RANKL inhibitor (monoclonal antibody) RANKL (receptor activator of nuclear factor kappa-B ligand) Oncology, Bone Health, Rheumatology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Fujian Cancer Hospital · 2 shared drug classes
  2. Innovent Biologics (Suzhou) Co. Ltd. · 2 shared drug classes
  3. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 2 shared drug classes
  4. Eli Lilly and Company · 2 shared drug classes
  5. GlaxoSmithKline · 2 shared drug classes
  6. Amgen · 2 shared drug classes
  7. Bio-Thera Solutions · 2 shared drug classes
  8. Jiangsu Alphamab Biopharmaceuticals Co., Ltd · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for mAbxience Research S.L.:

Cite this brief

Drug Landscape (2026). mAbxience Research S.L. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/mabxience-research-s-l. Accessed 2026-05-16.

Related